Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Lipocine ( (LPCN) ) has shared an announcement.
On December 16, 2025, Lipocine announced that its Phase 3 clinical trial for LPCN 1154, an oral formulation of brexanolone for postpartum depression (PPD), reached 80% enrollment. The trial, which aims to provide rapid relief for PPD, is expected to have topline results by the second quarter of 2026. The study’s progress suggests a strong unmet medical need in the PPD population, and the results could support a 505(b)(2) NDA submission in 2026. The announcement highlights Lipocine’s commitment to addressing significant unmet medical needs and could enhance its positioning in the biopharmaceutical industry.
The most recent analyst rating on (LPCN) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Lipocine stock, see the LPCN Stock Forecast page.
Spark’s Take on LPCN Stock
According to Spark, TipRanks’ AI Analyst, LPCN is a Neutral.
Lipocine’s overall stock score is primarily impacted by its financial performance and valuation. While the company shows signs of financial recovery with a strong balance sheet, ongoing profitability challenges and negative cash flow generation weigh heavily on the score. The technical analysis indicates a bearish trend, further contributing to the lower score. The lack of earnings call data and corporate events means these factors do not influence the score.
To see Spark’s full report on LPCN stock, click here.
More about Lipocine
Lipocine Inc. is a biopharmaceutical company that utilizes its proprietary technology platform to develop innovative products with effective oral delivery. The company focuses on creating differentiated patient-friendly oral delivery options targeting large markets with significant unmet medical needs. Lipocine’s development pipeline includes treatments for postpartum depression, major depressive disorder, treatment-resistant depression, epilepsy, essential tremor, obesity management, liver cirrhosis symptoms, and prevention of preterm birth.
Average Trading Volume: 43,684
Technical Sentiment Signal: Sell
Current Market Cap: $17.6M
For an in-depth examination of LPCN stock, go to TipRanks’ Overview page.